How does this happen? Part I: Mechanisms of adverse drug reactions associated with psychotropic medications

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 19, Issue 1, 2010, Pages 40-45

  Elbe, Dean ^a   Savage, Robert ^b  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b LIONS GATE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMILORIDE; AMPHETAMINE; ARIPIPRAZOLE; CLOMIPRAMINE; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HYDROCHLOROTHIAZIDE; LEVOTHYROXINE; LITHIUM; MESORIDAZINE; METHYLPHENIDATE; MIRTAZAPINE; MOXIFLOXACIN; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; ZIPRASIDONE;

ADVERSE DRUG REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPOTHYROIDISM; MAJOR DEPRESSION; MOOD DISORDER; NEPHROGENIC DIABETES INSIPIDUS; QT PROLONGATION; RISK FACTOR; SEXUAL DYSFUNCTION;

EID: 77949626716     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Angst, J. (1998). Sexual problems in healthy and depressed persons. International Clinical Psychopharmacology. 13(suppl 6), S1-S4.
2. Angulo, J., Peiro, C., Sanchez-Ferrer, P., Gabancho, S., Cuevas, P., Gupta, S. et al. (2001). Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. British Journal of Pharmacology, 134(6), 1190-1194.
3. Bedford, J. J. Weggery, S., Ellis, G., McDonald, F. J., Joyce, P. R., Leader, J. P., et al. (2008). Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clinical Journal of the American Society of Nephrology, 3(5), 1324-1331.
4. Cheetham, T., Baylis, P. H. (2002). Diabetes insipidus in children - pathophysiology, diagnosis and management. Pediatric Drugs, 4(12), 785-796.
5. Christensen, S., Kusano, E., Yusufi, A. N. K., Murayama, N., Dousa, T. P. (1985). Pathogenesis of Nephrogenic Diabetes Insipidus Due to Chronic Administration of Lithium in Rats. Journal of Clinical Investigation, 75(6), 1869-1879.
6. Corona, G., Ricca, V., Bandini, E., Mannucci, E., Lotti, F., Boddi, V. et al. (2009). Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction. Journal of Sexual Medicine, 6(5), 1259-1269.
7. Davies, P. H., Franklyn, J. A. (1991). The effects of drugs on tests of thyroid function. European Journal of Clinical Pharmacology, 40(5), 439-451.
8. European Medicines Agency (2005). The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. London, England, European Medicines Agency. Retrieved November 6, 2009 from http://www.emea.europa.eu/pdfs/human/ich/042302en.pdf
9. Glennon, R. A., Dukat, M., Westkaemper, R. B. (2000). Serotonin Receptor subtypes and ligands. Retrieved November 12, 2009 from http://www.acnp.org/g4/ GN401000039/Ch039.html
10. Grandjean, E. M., Aubry J. M. (2009). Lithium: Updated Human Knowledge Using an Evidence-Based Approach, Part III: Clinical Safety. CNS Drugs, 23(5), 397-418.
11. Grünfeld, J., Rossier, B. C. (2009). Lithium nephrotoxicity revisited. Nature Reviews Nephrology, 5, 270-276.
12. Haddad, P. M., Anderson, I. M. (2002). Antipsychotic-related QTc prolongation, Torsade de Pointes and Sudden Death. Drugs, 62(11), 1649-1671.
13. Harrigan, E. P., Miceli, J. J., Anziano, R., Watsky, E., Reeves, K. R., Cutler, N. R. et al (2004). A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition. Journal of Clinical Psychopharmacology, 24(1), 62-69.
14. Holt, R. I. G. (2008). Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. Journal of Psychopharmacology, 22 (suppl 2), 28-37.
15. Kao, L. W., Furbee, R. B. (2005). Drug-induced QTc prolongation. Medical Clinics of North America, 89(6), 1125-1144.
16. Keltner, N. L., McAfee, K. M., Taylor, C. L. (2002). Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspectives in Psychiatric Care, 38(3), 111-116.
17. Kennedy, S. H., Rizvi, S. (2009). Sexual Dysfunction, Depression, and the Impact of Antidepressants. Journal of Clinical Psychopharmacology, 29(2), 157-164.
18. Khanna, A. (2006). Acquired Nephrogenic Diabetes Insipidus. Seminars in Nephrology, 26(3), 244-8.
19. Kongsamut, S., Kang, J., Chen X., Roehr, J., Rampe, D. (2002). A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European Journal of Pharmacology, 450, 37-41.
20. La Torre, D., Falorni, A. (2007). Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management, 3(5), 929-951.
21. Livingstone, C., Rampes, H. (2006). Lithium: a review of its metabolic adverse effects. Journal of Psychopharmacology, 20(3), 347-355.
22. Marples, D., Christensen, S., Christensen, E. I., Ottosen, P. D., Nielsen, S (1995). Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. Journal of Clinical Investigation, 95, 1838-1845.
23. Meyer, J. M. (2008). Sexual dysfunction in patients treated with atypical antipsychotics. Journal of Clinical Psychiatry, 69(9), e26.
24. Morganroth, J., Brown, A. M., Critz, S., Crumb, W. J., Kunze, D. L., Lacerda, A. E. et al. (1993). Variability of the QTc Interval: Impact on Defining Drug Effect and Low-Frequency Cardiac Event. American Journal of Cardiology, 72(6), 26B-31B.
25. Pfizer Canada Inc. (2007). Zeldox® product monograph. Kirkland, QC: Pfizer Canada Inc. 2007.
26. Rosen, R. C., Lane, R., Menza, M. (1999). Effects of SSRIs on Sexual Function: A Critical Review. Journal of Clinical Psychopharmacology, 19(1), 67-85.
27. Scharko, A. M. (2004). Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction in Adolescents: A Review. Journal of the American Academy of Child and Adolescent Psychiatry, 43(9), 1071-1079.
28. Serretti, A., Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology, 29(3), 259-66.
29. Stahl, S. M. (1998). Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. Journal of Clinical Psychiatry, 59(suppl 4), 5-14.
30. Stryjer, R., Spivak, B., Strous, R. D., Shiloh, R., Harary, E., Polak, L. et al. (2009). Trazodone for the Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors: A Preliminary Open-Label Study. Clinical Neuropharmacology, 32(2), 82-84.
31. Swain, C. (2007). Open access and medicinal chemistry. Chemistry Central Journal, 1, 2-3.
32. Terao, T., Oga, T., Nozaki, S., Ohta, A., Otsubo, Y., Yamamoto, S. et al. (1995). Possible inhibitory effect of lithium on peripheral conversion of thyroxine to triiodothyronine: a prospective study. International Clinical Psychopharmacology, 10(2), 103-105.
33. Webb, D. J., Freestone, S., Allen, M. J., Muirhead, G. J. (1999). Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. American Journal of Cardiology, 83(5A), 21C-28C.
34. Woodrum, S. T., Brown, C. S. (1998). Management of SSRI-induced sexual dysfunction. Annals of Pharmacotherapy, 32(11), 1209-15.
35. Zemrak, W. R., Kenna, G. A. (2008). Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. American Journal of Health-System Pharmacy, 65(11), 1029-1038.